BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:28 PM
 | 
Sep 17, 2012
 |  BC Extra  |  Company News

IQWiG assesses Signifor's cost

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) said Cushing's disease drug Signifor pasireotide from Novartis AG (NYSE:NVS; SIX:NOVN) would cost the German statutory health insurance funds (GKV) EUR 8.6-EUR 19.3 million ($11.2-$25.2 million) per year. In an assessment requested by Germany's Federal Joint Committee...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >